FoRx Therapeutics is a clinical-stage biotechnology company developing small-molecule PARG inhibitors that target DNA replication stress in treatment-resistant cancers. In cancer, activating oncogene mutations and inactivating tumor suppressor mutations force cells to copy their DNA in an unscheduled, premature manner. FoRx develops precision cancer therapeutics through a pipeline of several small molecule programs addressing distinct DNA repair mechanisms, with FORX-428, an oral small molecule PARG inhibitor, as the lead candidate.
FORX-428 potently and selectively inhibits PARG, a key enzyme in the repair process. Cancer depends on DNA repair pathways, and inhibiting distinct repair components can selectively target tumor cells while sparing normal ones. FoRx pursues PARG as a next-generation DNA damage response target, and PARG inhibition targets patients whose cancers do not or no longer respond to PARP inhibitors.